Extracellular vesicles in disorders of hemostasis following traumatic brain injury

• DOI: 10.3389/fneur.2024.1373266
• Publication Date: 2024-05-09T05:26:05Z
• Authors: Aisling Mc Mahon; Luisa Weiss; Kathleen Bennett; Ger Curley; Fionnuala Ní Ainle; Patricia Maguire
• Keywords: 0301 basic medicine; 0303 health sciences; brain-derived extracellular vesicles; Neurology; traumatic brain injury; haemostasis; biomarkers; Neurology. Diseases of the nervous system; extracellular vesicles; RC346-429; thrombosis

Traumatic brain injury (TBI) is a global health priority. In addition to being the leading cause of trauma related death, TBI can result in long-term disability and loss health. Disorders haemostasis are common despite absence some traditional risk factors for coagulopathy following trauma. Similar induced coagulopathy, this manifests with biphasic response consisting an early hypocoagulable phase delayed hypercoagulable state. This clinically significant associated increased rates haemorrhagic expansion, death. The pathophysiology TBI-induced complex but there biologic plausibility emerging evidence suggest that extracellular vesicles (EVs) have role play. damage blood barrier release brain-derived EVs contain tissue factor phosphatidylserine on their surface. provides platform which coagulation occur. Preclinical animal models shown rapid results overwhelming activation resulting consumptive coagulopathy. phenomenon be attenuated administration substances promote EV clearance block effects. Small clinical studies demonstrated elevated levels procoagulant patients correlating outcome. represent promising opportunity use as minimally invasive biomarkers potential therapeutic targets patients. However, additional research necessary bridge gap between practical application settings.